Medicare approves Yescarta for cancer patients who will have a copayment of nearly $80,000

According to the Centers for Medicare and Medicaid Services, Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients who will have a co-payment of nearly $80,000. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.